Recursion Pharmaceuticals, Inc. (RXRX)
3.44
+0.06
(+1.78%)
USD |
NASDAQ |
Sep 03, 16:00
3.45
+0.01
(+0.29%)
Pre-Market: 08:00
Recursion Pharmaceuticals Research and Development Expense (TTM) : 344.11M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 344.11M |
| March 31, 2026 | 382.53M |
| December 31, 2025 | 425.27M |
| September 30, 2025 | 433.37M |
| June 30, 2025 | 396.21M |
| March 31, 2025 | 349.90M |
| December 31, 2024 | 296.13M |
| September 30, 2024 | 270.77M |
| June 30, 2024 | 266.88M |
| March 31, 2024 | 250.31M |
| December 31, 2023 | 232.67M |
| September 30, 2023 | 210.42M |
| Date | Value |
|---|---|
| June 30, 2023 | 184.57M |
| March 31, 2023 | 169.48M |
| December 31, 2022 | 155.32M |
| September 30, 2022 | 159.70M |
| June 30, 2022 | 152.11M |
| March 31, 2022 | 143.30M |
| December 31, 2021 | 134.97M |
| September 30, 2021 | 107.45M |
| June 30, 2021 | 90.76M |
| March 31, 2021 | 74.46M |
| December 31, 2020 | 63.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Twist Bioscience Corp. | 71.86M |
| Absci Corp. | 86.49M |
| Novavax, Inc. | 335.42M |
| Editas Medicine, Inc. | 82.53M |
| Halozyme Therapeutics, Inc. | 102.37M |